Benzinga | Jul 6, 2021 09:22AM EDT

Piper Sandler Initiates Coverage On Tempest Therapeutics with Overweight Rating, Announces Price Target of $23

Piper Sandler analyst Edward Tenthoff initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Overweight rating and announces Price Target of $23.